Reported Friday, Biohaven to Announce Topline Data for Troriluzole Spinocerebellar Ataxia Study, Conference Call Set for Sept 23
Reported Friday, Biohaven to Announce Topline Data for Troriluzole Spinocerebellar Ataxia Study, Conference Call Set for Sept 23
Biohaven Ltd. (NYSE:BHVN) (Biohaven), today announced that it will host a conference call to discuss topline data from Study BHV4157-206-RWE (NCT06529146), a study designed in discussion with the US Food and Drug Administration (FDA), to assess the effectiveness of troriluzole in Spinocerebellar Ataxia.
Biohaven有限公司 (紐交所:BHVN) (Biohaven) 今天宣佈將舉行電話會議，討論研究BHV4157-206-RWE (NCT06529146)的頭版數據，這是與美國食品和藥品監督管理局 (FDA) 討論設計的研究，旨在評估troriluzole在脊髓小腦性共濟失調中的有效性。
Biohaven will hold a live conference call and webcast Monday, September 23, 2024, at 8:30 a.m. Eastern Time. The live event may be accessed via the Investor Relations portion of Biohaven's website at . To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call.
Biohaven將於2024年9月23日（星期一）美國東部時間上午8:30舉行現場電話會議和網絡直播。可以通過Biohaven網站的投資者關係部分訪問現場活動。要參加現場電話會議，請在此註冊。註冊後，將提供撥入號碼和唯一的個人識別號以加入電話會議。
譯文內容由第三人軟體翻譯。